We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
News

Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5

Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
News

Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ipsogen SAS has announced that its breast cancer program results had been selected for presentation at the EBCC 5 congress, the 5th European Breast Cancer Conference, held in Nice, France, 21-25 March 2006.

The abstract titled "Identification and validation of a genomic predictor to distinguish classes of patients with distinct outcomes among poor prognosis breast tumours after anthracycline-based adjuvant therapy", has been selected by the EBCC-5 Scientific Committee for oral presentation in the session "How should we do phase II/III trials in the age of molecular biology?"

The session will be held on Wednesday 22 March 2006 and comprises talks from Invited Speakers along with the best submitted abstracts.

These results concern the identification on 323 patient samples and independent validation on 181 patient samples of a metagene-based predictor which is efficient to discriminate patients with unfavourable outcome after adjuvant anthracycline-based chemotherapy.

It uses a validated combination of genes known for their biological relevance, and is valid irrespective of the clinical centre. The test was validated in an independent cohort with patient samples from a multicentric clinical trial.

Advertisement